Rucaparib: a new treatment option for ovarian cancer

Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Domenica Lorusso

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-strand breaks, which results in a process known as 'synthetic lethality'. Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer. This includes the NGS Foundation Medicine evaluation of the role of this drug in the treatment algorithm of ovarian cancer. Moreover, perspectives on the future development of this drug are presented. Expert opinion: The FDA has approved this drug for the treatment of recurrent BRCA-mutated ovarian cancers, which were previously treated with at least two chemotherapies and has accepted the supplemental new drug application for maintenance use in patients who respond to platinum-based chemotherapy via the Prescription Drug User Fee Act (PDUFA) on 6 April 2018. European Medicines Agency (EMA) approval in the same setting is awaited. The possibility of using PARP inhibitors as a maintenance therapy, as a front-line therapy to combat recurrence, and in combination with anti-angiogenic agents and immune-therapies appears to be of particular interest.

Original languageEnglish
Pages (from-to)765-771
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number7
Publication statusPublished - May 2018


  • Female
  • Humans
  • Indoles/pharmacology
  • Ovarian Neoplasms/drug therapy
  • Poly(ADP-ribose) Polymerase Inhibitors/pharmacology


Dive into the research topics of 'Rucaparib: a new treatment option for ovarian cancer'. Together they form a unique fingerprint.

Cite this